Cygnus Technologies

Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes. Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process. Located in Southport, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.

PPD

PPD is now part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and PPD are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We now offer a comprehensive suite of world-class services across the clinical development spectrum – from scientific discovery, to assessing safety, efficacy, and health care outcomes, to managing clinical trial logistics, to the development and manufacturing of the drug product.

Alcami Corporation

Alcami is a US-based contract development, testing, and manufacturing organization for pharma and biotech companies. Since 1979, we support our clients in making their projects go from potential to reality day-after-day. Alcami recently announced the acquisition of Masy BioServices. Masy offers secure and tightly controlled GMP temperature storage from -196˚C to 70˚C, including all ICH stability conditions, for various materials including vaccines, biopharmaceuticals, cell banks, tissues, compounds, and medical devices. In addition, our pharma support services through Masy include equipment calibration, large-scale validation and qualification projects, SenseAnywhere monitoring system, and equipment sales and rentals. Core Capabilities: - Sterile fill-finish development and manufacturing - Oral solid dose development and manufacturing - Laboratory development & testing services Our mission is to unlock the potential of transformative medicines for our customers. We embody this passion through a supportive team environment, remarkable scientific expertise, and the Alcami University. If you are looking for a fulfilling career, you have come to the right place. Our employees are our biggest resource. Explore the career opportunities at Alcami today!